Company intelligence / Profile preview

ClavystBio

Ownership: Private
Development stage: Other

Overview

ClavystBio is a Temasek-backed life sciences venture builder and investor based in Singapore. It accelerates commercialization of life sciences breakthroughs by investing in and supporting early-stage biotech, medtech, and digital health startups across Asia. Since its founding in 2022, it has committed over US$220 million to early-stage ventures and funds. Its model emphasizes collaboration among academia, industry, investors, and infrastructure development to foster innovation from ideation through commercialization.

Modalities: Small moleculeAntibody-drug conjugateVaccineBiologic
Industry: Investors

Partnerships

academic institutionsindustry playersinvestors such as Lightstone Ventures and Vertex Growthpublic sector agencies like EDBI/SGInnovate

Beyond the preview

Go deeper on ClavystBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ClavystBio.

Explore the full profile